|
1
|
Khan MK, Khan N, Almasan A and Macklis R:
Future of radiation therapy for malignant melanoma in an era of
newer, more effective biological agents. Onco Targets Ther.
4:137–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bullard DE, Cox EB and Seigler HF: Central
nervous system metastases in malignant melanoma. Neurosurgery.
8:26–30. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang Z, Ahmad A, Li Y, Banerjee S, Kong D
and Sarkar FH: Forkhead box M1 transcription factor: A novel target
for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu XS, Miao RC, Wan Y, Zhang LQ, Qu K and
Liu C: FoxM1 as a novel therapeutic target for cancer drug therapy.
Asian Pac J Cancer Prev. 16:23–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wierstra I: FOXM1 (Forkhead box M1) in
tumorigenesis: overexpression in human cancer, implication in
tumorigenesis, oncogenic functions, tumor-suppressive properties,
and target of anticancer therapy. Adv Cancer Res. 119:191–419.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito T, Kohashi K, Yamada Y, Maekawa A,
Kuda M, Furue M and Oda Y: Prognostic significance of forkhead box
M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in
melanoma. Histopathology. 69:63–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miyashita A, Fukushima S, Nakahara S,
Yamashita J, Tokuzumi A, Aoi J, Ichihara A, Kanemaru H, Jinnin M
and Ihn H: Investigation of FOXM1 as a potential new target for
melanoma. PLoS One. 10:e01442412015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kruiswijk F, Hasenfuss SC, Sivapatham R,
Baar MP, Putavet D, Naipal KA, van den Broek NJ, Kruit W, van der
Spek PJ, van Gent DC, et al: Targeted inhibition of metastatic
melanoma through interference with Pin1-FOXM1 signaling. Oncogene.
35:2166–2177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhat UG, Zipfel PA, Tyler DS and Gartel
AL: Novel anticancer compounds induce apoptosis in melanoma cells.
Cell Cycle. 7:1851–1855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maachani UB, Shankavaram U, Kramp T,
Tofilon PJ, Camphausen K and Tandle AT: FOXM1 and STAT3 interaction
confers radioresistance in glioblastoma cells. Oncotarget.
7:77365–77377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Carlino MS, Todd JR, Gowrishankar K,
Mijatov B, Pupo GM, Fung C, Snoyman S, Hersey P, Long GV, Kefford
RF and Rizos H: Differential activity of MEK and ERK inhibitors in
BRAF inhibitor resistant melanoma. Mol Oncol. 8:544–554. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Carlino MS, Gowrishankar K, Saunders CA,
Pupo GM, Snoyman S, Zhang XD, Saw R, Becker TM, Kefford RF, Long GV
and Rizos H: Antiproliferative effects of continued
mitogen-activated protein kinase pathway inhibition following
acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol
Cancer Ther. 12:1332–1342. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Long GV, Fung C, Menzies AM, Pupo GM,
Carlino MS, Hyman J, Shahheydari H, Tembe V, Thompson JF, Saw RP,
et al: Increased MAPK reactivation in early resistance to
dabrafenib/trametinib combination therapy of BRAF-mutant metastatic
melanoma. Nat Commun. 5:56942014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang XD, Franco A, Myers K, Gray C,
Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing
ligand (TRAIL) receptor and FLICE-inhibitory protein expression to
TRAIL-induced apoptosis of melanoma. Cancer Res. 59:2747–2753.
1999.PubMed/NCBI
|
|
16
|
Pupo GM, Boyd SC, Fung C, Carlino MS,
Menzies AM, Pedersen B, Johansson P, Hayward NK, Kefford RF,
Scolyer RA, et al: Clinical significance of intronic variants in
BRAF inhibitor resistant melanomas with altered BRAF transcript
splicing. Biomark Res. 5:172017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Halasi M and Gartel AL: Suppression of
FOXM1 sensitizes human cancer cells to cell death induced by
DNA-damage. PLoS One. 7:e317612012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fahy BN, Schlieman MG, Mortenson MM,
Virudachalam S and Bold RJ: Targeting BCL-2 overexpression in
various human malignancies through NF-kappaB inhibition by the
proteasome inhibitor bortezomib. Cancer Chemother Pharmacol.
56:46–54. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Almond JB and Cohen GM: The proteasome: A
novel target for cancer chemotherapy. Leukemia. 16:433–443. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Park HJ, Carr JR, Wang Z, Nogueira V, Hay
N, Tyner AL, Lau LF, Costa RH and Raychaudhuri P: FoxM1, a critical
regulator of oxidative stress during oncogenesis. EMBO J.
28:2908–2918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Halasi M, Pandit B, Wang M, Nogueira V,
Hay N and Gartel AL: Combination of oxidative stress and FOXM1
inhibitors induces apoptosis in cancer cells and inhibits xenograft
tumor growth. Am J Pathol. 183:257–265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kinugasa H, Whelan KA, Tanaka K,
Natsuizaka M, Long A, Guo A, Chang S, Kagawa S, Srinivasan S, Guha
M, et al: Mitochondrial SOD2 regulates epithelial-mesenchymal
transition and cell populations defined by differential CD44
expression. Oncogene. 34:5229–5239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hosoki A, Yonekura S, Zhao QL, Wei ZL,
Takasaki I, Tabuchi Y, Wang LL, Hasuike S, Nomura T, Tachibana A,
et al: Mitochondria-targeted superoxide dismutase (SOD2) regulates
radiation resistance and radiation stress response in HeLa cells. J
Radiat Res. 53:58–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun Y, St Clair DK, Fang F, Warren GW,
Rangnekar VM, Crooks PA and St Clair WH: The radiosensitization
effect of parthenolide in prostate cancer cells is mediated by
nuclear factor-kappaB inhibition and enhanced by the presence of
PTEN. Mol Cancer Ther. 6:2477–2486. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Benlloch M, Mena S, Ferrer P, Obrador E,
Asensi M, Pellicer JA, Carretero J, Ortega A and Estrela JM: Bcl-2
and Mn-SOD antisense oligodeoxynucleotides and a glutamine-enriched
diet facilitate elimination of highly resistant B16 melanoma cells
by tumor necrosis factor-alpha and chemotherapy. J Biol Chem.
281:69–79. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee Y, Kim KH, Kim DG, Cho HJ, Kim Y,
Rheey J, Shin K, Seo YJ, Choi YS, Lee JI, et al: FoxM1 promotes
stemness and radio-resistance of glioblastoma by regulating the
master stem cell regulator Sox2. PLoS One. 10:e01377032015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kurland JF and Meyn RE: Protease
inhibitors restore radiation-induced apoptosis to Bcl-2-expressing
lymphoma cells. Int J Cancer. 96:327–333. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Avery-Kiejda KA, Zhang XD, Adams LJ, Scott
RJ, Vojtesek B, Lane DP and Hersey P: Small molecular weight
variants of p53 are expressed in human melanoma cells and are
induced by the DNA-damaging agent cisplatin. Clin Cancer Res.
14:1659–1668. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buch K, Peters T, Nawroth T, Sänger M,
Schmidberger H and Langguth P: Determination of cell survival after
irradiation via clonogenic assay versus multiple MTT Assay-a
comparative study. Radiat Oncol. 7:12012. View Article : Google Scholar : PubMed/NCBI
|
